Drug Profile

BW 1010

Alternative Names: BW-1010; rPA/NE01 anthrax vaccine

Latest Information Update: 28 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NanoBio Corporation; Public Health England
Developer BlueWillow Biologics; Porton Biopharma
Class Anthrax vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Anthrax

Most Recent Events

28 Dec 2024 No recent reports of development identified for phase-I development in Anthrax(Prevention) in USA (Intranasal, Spray)
28 Dec 2022 Phase I development in Anthrax (Prevention) is ongoing in USA (Intranasal) (BlueWillow Biologics pipeline, December 2022)
26 Oct 2021 BlueWillow Biologics plans a late-stage clinical trials for Anthrax (Prevention) (Intranasal) as early as 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com